Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Any type of Cancer

Active, not recruiting

2

Start Date 03/01/2014

Age of Trial (yrs) 11.1

All

BRAF Inhibitor + MEK Inhibitor

Block BRAF

Specifically GIST plus other cancers

117019

GlaxoSmithKline

US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com

Oral

Inquiries should be directed first to the GSK contacts.

There are 47 sites open or pending. 35 in Europe, 8 in the US, 3 in the Republic of Korea and 1 in Canada. Current site information is available in the trial listing at the clinicaltrials.gov site. Click on the NCT # and expand the Contacts and Locations section to se the most recent listings and status.

Subjects will need to have a fresh or frozen tumor tissue sample provided to confirm the BRAF V600E mutation status.

Only subjects with histologically confirmed advanced disease and no available standard treatment options will be eligible for enrollment.

Inclusion criteria: BRAF V600E mutation-positive tumor
French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.